z-logo
open-access-imgOpen Access
Treatment of 22q11.2 deletion syndrome-associated schizophrenia with comorbid anxiety and panic disorder
Author(s) -
Candace Borders,
Amanda Suzuki,
David Safani
Publication year - 2017
Publication title -
mental illness
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.239
H-Index - 10
eISSN - 2036-7465
pISSN - 2036-7457
DOI - 10.4081/mi.2017.7225
Subject(s) - panic disorder , asenapine , psychiatry , schizophrenia (object oriented programming) , anxiety , psychosis , panic , population , medicine , psychology , clinical psychology , antipsychotic , environmental health
22q11.2 deletion syndrome (22q11DS) is a risk factor for psychiatric illnesses, including schizophrenia and anxiety. Small studies have shown that several neuroleptic medications are effective in treating psychosis in this population, but are also associated with an increased risk of adverse effects - particularly, seizures. In this case, we discuss a 34-year-old patient presenting with late onset schizophrenia, which ultimately led to her diagnosis of 22q11DS. Subsequent management of the patient’s psychosis with asenapine was complicated by concurrent anxiety and panic disorder; thus, we examine the role of anxiolytic therapy in conjunction with antipsychotics in this patient population

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom